Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29974781 | 1.00 | CCR8 (0.46) | CCR8KMT2AALDH1A1HSD17B10KDM4E | |
| SCHEMBL21050882 | 0.85 | CCR8 (0.47) | CCR8KMT2AALDH1A1HSD17B10KDM4E | |
| SCHEMBL21050799 | 0.80 | CCR8 (0.46) | CCR8KMT2AALDH1A1HSD17B10KDM4E | |
| SCHEMBL1886773 | 0.75 | CCR8 (0.52) | CCR8KMT2AALDH1A1HSD17B10KDM4E | |
| SCHEMBL29974598 | 0.71 | EIF4A3 (0.42) | KDM4E | |
| SCHEMBL27164027 | 0.71 | EIF4A3 (0.42) | KDM4E | |
| SCHEMBL18128491 | 0.71 | F2 (0.34) | — | |
| SCHEMBL30077845 | 0.71 | F2 (0.34) | — | |
| SCHEMBL21243088 | 0.70 | CSNK2A1 (0.42) | CCR8KMT2ATNFRIPK1CSNK2A1 | |
| SCHEMBL31341960 | 0.70 | CSNK2A1 (0.38) | CCR8KMT2ATNFRIPK1CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4548918-A2 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250059179-A1 | Heterocyclic Compounds and Methods of Use | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4329888-A1 | 2-AMINOBENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | Amgen Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117651700-A | 2-aminobenzothiazole compounds and methods of use | 安进公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-116332948-A | Nitrogen-containing tetracyclic compound, preparation method and medicinal application thereof | 翰森生物有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230192696-A1 | SPIRO COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-20230192696-A1 | SPIRO COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-20230192696-A1 | SPIRO COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-11530218-B2 | Spiro compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2022-12-20 | — | — | US | disclosed |
| EP-4087843-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2022-11-16 | — | — | EP | disclosed |
| WO-2021150613-A1 | SPIRO COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2021-07-29 | — | — | WO | disclosed |
| US-20210230162-A1 | SPIRO COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2021-07-29 | — | — | US | disclosed |
| US-20210230162-A1 | SPIRO COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2021-07-29 | — | — | US | disclosed |
| US-10597405-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-24 | — | — | US | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | KRAS, RSU1, NRAS | CCR8 2710/4885KMT2A 3631/4885ALDH1A1 3991/4885 |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | CCR8 2420/4885KMT2A 1959/4885ALDH1A1 26/4885 |
| US-10597405-B2 | Chemical compounds | MKI67, CCNI, MCL1 | CCR8 2420/4885KMT2A 1959/4885ALDH1A1 26/4885 |
| US-20250059179-A1 | Heterocyclic Compounds and Methods of Use | KRAS, NRAS, HRAS | CCR8 2733/4885KMT2A 2621/4885ALDH1A1 1275/4885 |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | CCR8 3184/4885KMT2A 3565/4885ALDH1A1 2204/4885 |
| US-20230192696-A1 | SPIRO COMPOUNDS AS INHIBITORS OF KRAS | KRAS, HRAS, NRAS | CCR8 3217/4885KMT2A 4025/4885ALDH1A1 799/4885 |
| US-20210230162-A1 | SPIRO COMPOUNDS AS INHIBITORS OF KRAS | KRAS, HRAS, NRAS | CCR8 3217/4885KMT2A 4025/4885ALDH1A1 799/4885 |
| US-11530218-B2 | Spiro compounds as inhibitors of KRAS | KRAS, HRAS, NRAS | CCR8 3163/4885KMT2A 4083/4885ALDH1A1 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.